1 / 27

Module 5: Principles of Treatment

Module 5: Principles of Treatment. Session Overview Aims of TB Treatment General Principles Treatment Guidelines. Learning Objectives. Describe 3 basic principles of TB treatment Explain the difference between the 4 treatment categories (Cat I-IV)

faith
Download Presentation

Module 5: Principles of Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Module 5: Principles of Treatment Session Overview • Aims of TB Treatment • General Principles • Treatment Guidelines

  2. Learning Objectives • Describe 3 basic principles of TB treatment • Explain the difference between the 4 treatment categories (Cat I-IV) • Understand and describe when and why a regimen may be extended

  3. Aims of TB Treatment • Cure the patient of TB • Prevent death from active TB or its latent effects • Prevent relapse of TB • Decrease transmission of TB to others • Prevent the development of acquired resistance

  4. Fundamental Responsibility and Approach in TB Treatment • Assure that appropriate regimen is prescribed by MOs • Ensure successful completion of therapy (adherence) • Utilize directly observed therapy (DOT) as standard-of-care

  5. Adherence • Nonadherence is a major problem in TB control • Patient education is the most effective tool to prevent default—USE IT!! • Use case management and directly observed therapy (DOT) to ensure patients complete treatment

  6. Why Do Patients Default? • As their condition improves they may feel better and decide they don’t need meds • They may experience side effects • Forgetfulness/lack of a reminder! • Travel to cattle posts without refills • Difficulty getting to clinic b/c of work/distance

  7. What is Case Management? • Assignment of responsibility within clinic to • oversee patient monitoring • -bacteriology • -DOT • -side effects • Systematic regular review of patient data • Plans in place to address barriers to adherence BEFORE default occurs

  8. Directly Observed Therapy (DOT) • Health care worker watches patient swallow • each • -Dose of medication • -Every pill, every day • -Self-administered is NOT DOT • REMEMBER • DOT for all patients on all regimens • NO exceptions

  9. DOT in Ghantsi…Can you identify the main elements?

  10. Directly Observed Therapy (DOT) • DOT can lead to reductions in relapse and acquired drug resistance • Use DOT with other measures to promote adherence • DOT is the key to CURE

  11. Treatment of TB Disease

  12. Epidemiologic information e.g., circulating strains, resistance patterns Clinical, pathological, chest x-ray findings Microscopic examination of acid-fast bacilli (AFB) in sputum smears Factors Guiding Treatment Initiation

  13. Basic Principles of Treatment • Determine the patient’s HIV status- this could save their life! • Provide safest, most effective therapy in shortest time • Multiple drugs to which the organisms are susceptible • Never add single drug to failing regimen • Ensure adherence to therapy (DOT)

  14. Standard Treatment Regimen • Initial phase: standard four drug regimens (INH, RIF, PZA, EMB), for 2 months • Continuation phase: additional 4 months

  15. Treatment of TB for HIV-Negative Persons • 2 months HRZE followed by 4HR • Four drugs in initial regimen always • Isoniazid (INH) • Rifampin (RIF) • Pyrazinamide (PZA) • Ethambutol (EMB) or streptomycin (SM) • (Streptomycin replaces Ethambutol in TB meningitis)

  16. Treatment of TB for HIV-Positive Persons • Management of HIV-related TB is complex • and patient care needs to be coordinated with • IDCC • HIV-infected patients already on ARVs who develop TB should begin anti-TB meds immediately • Patients on 1st line ARVs may start Category I ATT. • Patients on ARV regimen with efavirenz • should be reviewed by a specialist. • If patient is on 2nd or 3rd line ARVs discuss with specialist before starting ATT.

  17. Treatment of TB for HIV-Positive Persons • HIV-infected TB patients should be evaluated for ARVs immediately • Pts with CD4<=200 should start ARVs within two weeks after start of ATT • Pts with CD4s>200 may defer until end of ATT

  18. Extrapulmonary TB • In most cases, treat with same regimens • used for pulmonary TB Bone and Joint TB, Miliary TB, or TB Meningitis in Children • Treatment extended > 6 months depending on site of disease • In TB meningitis Streptomycin replaces Ethambutol

  19. Infants and Children • Children • Children are at an increased risk for TB disease • If the disease is severe (meningitis, military TB, etc.) use Category I treatment, SM replaces EMB in small children • For less severe disease: treat with category III regimen • In most cases, treat with same regimens used for adults Infants • Treat as soon as diagnosis is suspected

  20. Dosing of CPT in Children

  21. Multidrug-Resistant TB (MDR TB) • Presents difficult treatment problems • Lengthy, multi-drug regimen • Side effects common • Management complex • Treatment must be individualized • Clinicians unfamiliar with treatment of MDR TB should seek expert consultation • Always use DOT to ensure adherence

  22. Multidrug-Resistant TB (MDR TB) Con’t • 6 months intensive treatment (always including an injectable drug) followed by at least an 18 month continuation phase • Only specialist physicians at the referral hospitals can initiate MDR treatment

  23. Treatment Monitoring • Sputum smear microscopy for AFB at 2 months and 6 months • If positive at two months, repeat at 3 • If still smear positive at 3 months, continuation phase (4HR) is still started while awaiting DST results • Continue drug-susceptibility tests if smear-positive after 3 months of treatment

  24. Adverse Drug Reactions

  25. Adverse Drug Reactions

  26. Common Adverse Drug Reactions

  27. Drug Interactions • Relatively few drug interactions substantially change concentrations of antituberculosis drugs • Antituberculosis drugs sometimes change concentrations of other drugs -Rifamycins can decrease serum concentrations of many drugs, (e.g., most of the HIV-1 protease inhibitors), to subtherapeutic levels -Isoniazid increases concentrations of some drugs (e.g., phenytoin) to toxic levels

More Related